Drugmaker Endo International PLC said it would comply with a Food and Drug Administration request to remove the opioid painkiller Opana ER from the U.S. market, which the FDA said was necessary due to the medication’s links to injection drug abuse.

The FDA last month asked Endo to stop selling the drug, in what the agency called its first effort to remove an opioid pain drug from the market over abuse concerns.

Endo...